Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Atavistik Bio, Inc
K36 Therapeutics, Inc.
Varian, a Siemens Healthineers Company
M.D. Anderson Cancer Center
University of California, Davis
National Institutes of Health Clinical Center (CC)
University of California, Irvine
Blue Earth Therapeutics Ltd
Cedars-Sinai Medical Center
Indiana University
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
AgonOx, Inc.
Memorial Sloan Kettering Cancer Center
RenJi Hospital
M.D. Anderson Cancer Center
Eli Lilly and Company
The Netherlands Cancer Institute
Queen Mary University of London
Pathos AI, Inc.
University of California, San Francisco
British Columbia Cancer Agency
Dana-Farber Cancer Institute
Milton S. Hershey Medical Center
Ottawa Hospital Research Institute
Marengo Therapeutics, Inc.
Eli Lilly and Company
University of California, Irvine
Endocyte
Stanford University
Novartis
Algemeen Ziekenhuis Maria Middelares
Poseida Therapeutics, Inc.
Sharp HealthCare
University Teaching Hospital Hall in Tirol
VA Greater Los Angeles Healthcare System
Mabwell (Shanghai) Bioscience Co., Ltd.
University of Toronto
Mayo Clinic
Universitaire Ziekenhuizen KU Leuven
Advaxis, Inc.
Promontory Therapeutics Inc.
National Institutes of Health Clinical Center (CC)
Milton S. Hershey Medical Center
Steba Biotech S.A.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group